Prospects for Induced Pluripotent Stem Cell-Derived Hepatocytes in Cell Therapy1

Cell Medicine

Kazuhide Yamamoto¹  Masaya Iwamuro¹  Naoya Kobayashi²  Javed M. Shahid² 

[1] *Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan;†Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

关键词: Induced pluripotent stem (iPS) cells;    Hepatic differentiation;    Hepatocytes;   

DOI  :  10.3727/215517911X575975

学科分类：生物科学（综合）

来源: Cognizant Communication Corporation

【 摘 要 】

Induced pluripotent stem (iPS) cells, first established in 2006, have the same characteristics of self-renew-ability and pluripotency as embryonic stem (ES) cells. iPS cells are inducible from patient-specific somatic cells; therefore, they hold significant advantages for overcoming immunological rejection as well as the ethical issues associated with the derivation of ES cells from embryos. Generation of patient-derived hepatocytes by iPS technology and their use in cell transplantation therapy for patients with liver disease is quite attractive. Here, we discuss recent advances and challenges in hepatocyte differentiation from iPS cells and their utility in cell therapy.

【 授权许可】

CC BY